Harpoon Shares Drop 7.3% as AbbVie Declines License Option
September 13 2023 - 5:12PM
Dow Jones News
By Ben Glickman
Shares of Harpoon Therapeutics fell Wednesday after the company
said AbbVie wouldn't exercise an exclusive license option on one of
its treatments.
The stock was down 7.3% to $6.06 after-hours, after falling 4%
at Wednesday's close. Shares are down 9.9% this year.
The South San Francisco, Calif.-based immuno-oncology company
said that under an agreement set to expire Oct. 12, AbbVie had an
exclusive license option on HPN217, a program made by Harpoon which
targets B cell maturation antigen.
Harpoon plans to complete the current Phase 1 trial to continue
developing the drug.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 13, 2023 16:57 ET (20:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Apr 2024 to May 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From May 2023 to May 2024
